Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31156183 | 1.00 | MEN1 (0.47) | MEN1KMT2ACYP2A6NPC1RAB9A | |
| SCHEMBL10896655 | 0.80 | USP7 (0.53) | MEN1KMT2ACYP2A6NPC1RAB9A | |
| SCHEMBL17436303 | 0.80 | LCK (0.42) | MEN1KMT2ANPC1RAB9ALCK | |
| SCHEMBL31743301 | 0.79 | LCK (0.43) | LCKKDRJAK3MAPK14TRPA1 | |
| SCHEMBL27586879 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2ACYP2A6NPC1RAB9A | |
| SCHEMBL11231194 | 0.78 | CYP2A6 (0.53) | MEN1KMT2ACYP2A6NPC1RAB9A | |
| SCHEMBL1744099 | 0.77 | CYP2A6 (0.47) | MEN1KMT2ACYP2A6NPC1RAB9A | |
| SCHEMBL12349146 | 0.77 | CTSD (0.54) | MEN1KMT2ANPC1RAB9APIK3CD | |
| SCHEMBL22241877 | 0.77 | PDE10A (0.54) | CYP2A6ALDH1A1ALOX5APFEN1PDE10A | |
| SCHEMBL31434702 | 0.77 | OXTR (0.43) | LCKKDRJAK3MAPK14TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| EP-1659112-B1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET SOC CIV (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1659112-B1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET SOC CIV (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1659112-A1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET (FR) | 2006-05-24 | — | — | EP | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| EP-0017438-B1 | SUBSTITUTED 3-ALKYL-6-PHENYL-1,2,4-TRIAZOLO(4,3-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AMERICAN CYANAMID COMPANY (US) | 1983-03-02 | — | — | EP | disclosed |
| US-4242515-A | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines | AMERICAN CYANAMID COMPANY (US) | 1980-12-30 | — | — | US | disclosed |
| EP-0017438-A1 | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo(4,3-a)pyridines, processes for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1980-10-15 | — | — | EP | disclosed |
| US-4209626-A | Substituted 6-phenyl-1,2,4-triazolo[4,3-a]pyridines | AMERICAN CYANAMID COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | DRD2, HTR2C, DRD3 | MEN1 4650/4885KMT2A 3301/4885CYP2A6 467/4885 |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | CYP4Z1, CYP3A5, CYP1A2 | MEN1 4114/4885KMT2A 2505/4885CYP2A6 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.